Microba Life Sciences (ASX:MAP) received firm commitments to raise around AU$12.5 million through the issue of 138.9 million shares at AU$0.09 each, according to a Monday filing with the Australian bourse.
The issue price represents a 21.7% discount to the company's last closing price on June 18.
Participants will also receive one free unlisted attaching option for every two new shares. The options will have an exercise price of AU$0.14 with a two-year expiry from the date of issue, the filing added.
The company said it will also open a share purchase plan (SPP) to raise up to AU$2 million, offering eligible shareholders the opportunity to acquire up to AU$30,000 worth of shares at the same offer price, the filing said.
Proceeds will be used to drive clinical adoption of the company's microbiome testing products.
The company also narrowed its fiscal year revenue guidance of AU$15.4 million to AU$16 million, from the previous AU$15.25 million to AU$16.25 million.
Cnaccord Genuity in Australia and Morgans Corporate are the joint lead managers for the placement.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。